Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 15, 2025Journal of Clinical MedicineOpen Access

Does the Timing of Response Impact the Outcome of Relapsed/Refractory Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents? A Proof of Concept from a Monocentric Observational Study

View Full Paper
Ask AI
Bookmark
Share

Authors

ELErmelinda LongoPoliclinico Universitario di CataniaFPFanny Erika PalumboVita-Salute San Raffaele UniversityADAndrea DuminucoGuy's and St Thomas' NHS Foundation Trust

Discussion

Loading...

Member takes

Implication

Observational study shows comparable outcomes for early and late responders in R/R AML, suggesting flexible treatment schedules are feasible.

Key Points

  • Treatment with HMA-VEN achieved a composite complete remission rate of 58% in R/R AML patients, demonstrating effectiveness.
  • No significant differences in overall survival were observed between early and late responders, implying flexibility in treatment timing is possible.
  • Patients treated with HMA-VEN reported manageable toxicities, including neutropenia, which is a common side effect of such therapies.
  • The study suggests that late responders do not face a prognostic disadvantage, indicating continued therapy may be beneficial.

Cite This Study

Longo et al. (2025) studied this question.

synapsesocial.com/papers/68a365600a429f797332b588https://doi.org/10.3390/jcm14155586
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical management of patients diagnosed with acute myeloid leukemia treated with venetoclax in combination with hypomethylating agents after achieving a response: a real-life study2024 · 6 citations
  2. 2Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first‐line therapy with hypomethylating agents alone or in combination with Venetoclax2023 · 24 citations
  3. 3Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort2018 · 150 citations
  4. 4An update of current treatments for adult acute myeloid leukemia2015 · 574 citations
  5. 5Real-life monocentric experience of venetoclax-based regimens for acute myeloid leukemia2023 · 15 citations